Cargando…
Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial
BACKGROUND: High levels of circulating fibroblast growth factor 23 (FGF23) are associated with chronic kidney disease (CKD) progression and high mortality. In the Phosphate Reduction Evaluation of FGF23 in Early CKD Treatment (PREFECT) study, we assessed the effect of reducing intestinal phosphate a...
Autores principales: | Ureña-Torres, Pablo, Prié, Dominique, Keddad, Karim, Preston, Peter, Wilde, Paul, Wan, Hong, Copley, J Brian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107721/ https://www.ncbi.nlm.nih.gov/pubmed/24885942 http://dx.doi.org/10.1186/1471-2369-15-71 |
Ejemplares similares
-
Meeting with the Sub-Prefect of Gex
Publicado: (1985) -
Chaptal's Letter to the Prefects, on Vaccination
por: Ring, John
Publicado: (1805) -
Association between serum fibroblast growth factor‐23 concentration and development of hyperphosphatemia in normophosphatemic dogs with chronic kidney disease
por: Miyakawa, Hirosumi, et al.
Publicado: (2021) -
Visit of Chantal Mauchet, Prefect of Ain, in France
por: Cavazza, Marina
Publicado: (2023) -
Beneficial Response to Phosphate Lowering Therapy in Normophosphatemic Tumoral Calcinosis
por: Soumya, Sarayu, et al.
Publicado: (2021)